We are happy and proud to finally announce that CarboHyde won a 2024-1.2.7-EUROSTARS-2025-00007 grant and shall receive ~190,000k Eur to develop a novel cyclodextrin-based Alzheimer asset.
The development will be done in a consortium involving Renatus and Ajou University.
The novel mechanism of action focuses on cholesterol modulation in this neurodegenerative disease and will aim to complete most IND enabling preclinical studies so that regulatory filings and clinical studies can begin shortly.
